| Literature DB >> 33385294 |
Norimichi Hattori1, Misuzu Sato2, Yuka Uesugi3, Ayaka Nakata3, Yohei Sasaki3, Shotaro Shimada3, Megumi Watanuki3, Shun Fujiwara3, Yukiko Kawaguchi3, Nana Arai3, Yui Uto3, Tomoharu Matsui3, Kouji Yanagisawa3, Sachiko Tahara2, H Phillip Koeffler4, Keiichi Iezumi2, Tsuyoshi Nakamaki3.
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is an uncontrolled hyperinflammatory disorder driven by an overactive immune system that results in high mortality. Post-transplant-associated hemophagocytic lymphohistiocytosis (PT-HLH) is a type of secondary HLH that occurs following allogeneic hematopoietic stem cell transplantation (allo-HSCT). The clinical features of PT-HLH remain unclear and diagnostic and prognostic tools have not yet been established. Here, we retrospectively evaluated the clinical manifestations and outcomes of PT-HLH in 94 patients who underwent allo-HSCT. According to our PT-HLH criteria (hyperferritinemia and increased macrophage count in bone marrow), PT-HLH occurred in 12 patients (12.8%). The PT-HLH patients showed splenomegaly (P = .001), a higher risk of engraftment failure (P = .013), and an increased percentage of macrophages and hemophagocytes in bone marrow aspirates (P = .0009 and P = .0006, respectively). Moreover, univariate and multivariate analyses revealed that the survival rate was lower in PT-HLH patients than non-PT-HLH patients (P = .0017 and P = .034, respectively). This study defines the clinical features of PT-HLH and PT-HLH criteria that could be useful tools for diagnosing PT-HLH.Entities:
Keywords: Allogeneic hematopoietic stem cell transplantation; Hemophagocytic lymphohistiocytosis; Hemophagocytosis; Hyperferritinemia; Post-transplant-associated hemophagocytic lymphohistiocytosis
Year: 2021 PMID: 33385294 DOI: 10.1007/s12185-020-03067-6
Source DB: PubMed Journal: Int J Hematol ISSN: 0925-5710 Impact factor: 2.490